DexCom (NASDAQ:DXCM) Price Target Increased to $160.00 by Analysts at Raymond James

DexCom (NASDAQ:DXCM) had its price target upped by research analysts at Raymond James from $151.00 to $160.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a “strong-buy” rating on the medical device company’s stock. Raymond James’ target price would suggest a potential upside of 27.20% from the stock’s previous close.

Several other brokerages have also issued reports on DXCM. Citigroup increased their price objective on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Canaccord Genuity Group boosted their target price on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday. Finally, Royal Bank of Canada began coverage on DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $141.67.

DexCom Trading Down 8.9 %

NASDAQ DXCM traded down $12.22 on Friday, hitting $125.79. 5,428,794 shares of the stock were exchanged, compared to its average volume of 3,006,353. The company’s 50-day moving average price is $130.98 and its two-hundred day moving average price is $118.02. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom has a 52-week low of $74.75 and a 52-week high of $142.00. The company has a market capitalization of $49.82 billion, a price-to-earnings ratio of 97.41, a P/E/G ratio of 2.37 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 28.31% and a net margin of 14.95%. Research analysts predict that DexCom will post 1.76 EPS for the current year.

Insiders Place Their Bets

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the transaction, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of DexCom stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the sale, the executive vice president now owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock valued at $25,530,859 in the last 90 days. 0.41% of the stock is currently owned by insiders.

Institutional Trading of DexCom

Institutional investors and hedge funds have recently modified their holdings of the stock. Stableford Capital II LLC increased its stake in DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after purchasing an additional 88 shares in the last quarter. D Orazio & Associates Inc. grew its holdings in shares of DexCom by 0.8% in the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after buying an additional 93 shares during the period. Gulf International Bank UK Ltd raised its holdings in DexCom by 0.3% during the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after buying an additional 93 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of DexCom by 10.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after buying an additional 98 shares during the period. Finally, Harbor Investment Advisory LLC boosted its stake in DexCom by 13.1% in the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock worth $120,000 after purchasing an additional 100 shares during the period. 97.75% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.